Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous and haemodialysis use. It is used to prevent and treat venous thromboembolism and to provide anticoagulation during haemodialysis in adult patients. GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Ledraxen is a low molecular weight heparin that acts on the coagulation cascade to prevent and treat thromboembolic disorders. - Deep vein thrombosis: prevents clot formation and treats existing DVT in at‑risk patients. - Pulmonary embolism: reduces the risk of PE development and assists in the treatment of established PE. - Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clot formation during dialysis sessions.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or bruising: mild discomfort at the injection site. - Minor bleeding: nosebleeds, gum bleeding, or easy bruising. - Nausea or mild gastrointestinal upset. - Headache: transient and usually self‑limiting. - Elevated liver enzymes: mild, transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major bleeding: internal hemorrhage, gastrointestinal or intracranial bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet count drop. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Spinal or epidural hematoma: rare but severe bleeding in neuraxial sites. - Severe liver injury: rare cases of hepatic dysfunction.

Use of Ledraxen requires careful clinical assessment. - Renal impairment: evaluate kidney function and adjust dose if needed. - Bleeding risk: assess for active bleeding or high‑risk conditions before initiation. - Surgical procedures: discontinue according to recommended timing before invasive surgery. - Concomitant anticoagulants or antiplatelet agents: monitor coagulation parameters closely. - Pregnancy and lactation: safety data are limited; use only if clearly indicated. - Store below 25°C: keep in the original container, protect from moisture and light.

Enoxaparin may interact with several drug classes.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): increased risk of severe bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect. - Fibrinolytic therapy (e.g., alteplase): heightened hemorrhagic potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate bleeding.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): modest increase in bleeding tendency. - ACE inhibitors or ARBs: monitor renal function and blood pressure. - Concomitant heparin products: cumulative anticoagulant effect requires dose adjustment.